Ionis Pharmaceuticals Inc
IONS
ISIN null / Valor 30877188
Ionis Pharmaceuticals Inc
UMushroom community rating:
About company
Ionis Pharmaceuticals Inc., headquartered in Carlsbad, California, is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics. Established in 1989, Ionis has pioneered the field of antisense technology, which involves designing drugs to bind to specific RNA molecules, thereby modulating the production of proteins associated with various diseases. The company has a robust pipeline of drugs targeting a range of conditions, including cardiovascular, neurological, and rare diseases. A notable product in their portfolio is TRYNGOLZA™ (olezarsen), which is aimed at treating conditions related to elevated triglycerides. Ionis operates independently in the U.S. market while leveraging strategic partnerships to expand its global reach. Additionally, its wholly-owned subsidiary, Akcea Therapeutics, focuses on developing and commercializing treatments for patients with serious and rare diseases. Ionis is publicly traded on the Nasdaq under the ticker symbol IONS.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (19.11.2025):
Ionis Pharmaceuticals Inc's second quarter 2025 financial results demonstrate strong momentum with substantial growth in revenue and a progressive outlook driven by the successful launch of TRYNGOLZA, increased royalty income, and robust research and development collaboration revenues. The company’s strategic investments in commercialization and key pipeline programs, including donidalorsen and pivotal Phase 3 studies, have supported not only a doubling of revenue compared to Q2 2024 but also an upward revision in its full-year financial guidance.
Revenue Growth
For Q2 2025, Ionis Pharmaceuticals Inc experienced a significant increase in commercial revenue, with product sales from TRYNGOLZA generating $19 million and overall commercial revenue rising 43% year-over-year. In addition, higher royalty revenues from its partnered medicines further bolstered total revenue, underscoring the strength of both its marketed and development-stage products.
Operating Efficiency and Investments
Operating expenses saw a modest single-digit increase due to targeted investments in commercialization efforts and preparing for the launches of donidalorsen and other pipeline therapies. A reduction in R&D expenses, as some late-stage studies concluded, helped mitigate overall cost increases while supporting the company’s operational leverage strategy.
Enhanced Financial Guidance
The improved outlook for 2025 is reflected in the raised financial guidance, driven by strong year-to-date revenue performance. This bullish guidance is a result of early sales momentum with TRYNGOLZA as well as encouraging licensing achievements and collaborative revenue gains from high-potential partnership programs.
Key Program Milestones
Notable program highlights for Q2 2025 include the early commercial success of TRYNGOLZA, anticipated regulatory milestones for donidalorsen in hereditary angioedema, and upcoming Phase 3 data in severe hypertriglyceridemia from the CORE and CORE2 studies. These developments position Ionis Pharmaceuticals Inc well for future market expansion and patient impact.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
11844 M
Market cap (USD)
3,208,760
Daily traded volume (Shares)
35.5 / 34.85
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Enzo Kekligian
EQUITIES OF THE SAME SECTOR
